SCHEMBL7243647

SCHEMBL7243647

O=C(Cl)c1ccc2cc[nH]c2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.70
HSD17B10 Q99714 2/20 0.70
ENPP2 Q13822 2/20 0.70
KDM4E B2RXH2 2/20 0.70
HPGD P15428 1/20 0.70
AHR P35869 3/20 0.52
CMA1 P23946 1/20 0.52
TYR P14679 1/20 0.52
GHSR Q92847 2/20 0.50
MAPT P10636 2/20 0.50
TAS1R3 Q7RTX0 1/20 0.50
TAS1R1 Q7RTX1 1/20 0.50
MAPK14 Q16539 1/20 0.49
ESR1 P03372 3/20 0.49
CYP2A6 P11509 1/20 0.47
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
CHRNA7 P36544 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC4 P56524 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1616468 0.85 F2 (0.58) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL29583385 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL50542 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL4595294 0.82 ALDH1A1 (1.00) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL23519010 0.81 ALDH1A1 (0.70) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL30201702 0.81 ALDH1A1 (0.70) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL121922 0.81 ALDH1A1 (0.70) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL28812839 0.81 ALDH1A1 (0.70) ALDH1A1HSD17B10ENPP2KDM4EHPGD
SCHEMBL24890385 0.81 ALDH1A1 (0.70) ALDH1A1HSD17B10ENPP2KDM4EHPGD
Hydrochloric Acid SCHEMBL1373044 0.81 ALDH1A1 (0.96) ALDH1A1HSD17B10ENPP2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103992316-A Method for synthesizing 5-formonitrile-pyrrole [1,2-a ] quinoline derivative NANJING UNIVERSITY OF TECHNOLOGY 2014-08-20 CN disclosed
CN-103992317-A Synthesis method of 5-formonitrile-pyrrole [1,2-a ] quinoline derivative NANJING UNIVERSITY OF TECHNOLOGY 2014-08-20 CN disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 WO disclosed
US-6566373-B2 For therapy of osteoporosis, periodontitis, and arthritis SMITHKLINE BEECHAM CORPORATION 2003-05-20 US disclosed
EP-1003846-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2002-11-13 EP disclosed
US-20020013360-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2002-01-31 US disclosed
EP-1003846-A1 PROTEASE INHIBITORS Smithkline Beecham (US) 2000-05-31 EP disclosed
WO-1998050533-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1998-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013360-A1 Protease inhibitors CTSK, CTSV, CTSS ALDH1A1 3469/4885HSD17B10 418/4885ENPP2 1736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.